Significant readouts for small players

Evaluate Vantage has already previewed important upcoming second-quarter data for big pharma and large biotech groups. Now it is the turn of companies with a market cap under $1bn.

Praxis hopes to differentiate its Gaba-A modulator from Sage/Biogen’s offering in depression, while Relmada is looking to position its NMDA receptor antagonist in the same space. Also, Alzheimer’s data are expected for Athira and Taurx, both of which are keen to draw a line under earlier tribulations.